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Small-cell carcinoma (SmCC) of the gastrointestinal tract is a very rare and aggressive malignancy. To better define its
clinicopathological features, the records of all patients with this disease seen at Memorial Sloan Kettering Cancer Center between
1980 and 2002 (n¼64) were reviewed. The most common primary tumour locations were in the large bowel and oesophagus.
Predisposing medical conditions for non-small-cell cancers, positive family cancer history, and metachronous tumours were common.
In all, 37% had mixed tumour histology and 48% presented with extensive disease, according to the Veterans’ Administration Lung
Study group (VALSG) staging system used for small-cell lung cancer. Treatment outcome in limited disease (LD) suggested a role for
surgery and chemotherapy. Platinum-based regimens resulted in a 50% response rate. The 2-year survival was 23% and two
prognostic factors were identified, the extent of disease according to the VALSG system (Po0.01) and TNM stage (P¼0.03).
Anatomic location had no clinical impact. In conclusion, SmCC from various gastrointestinal sites can be viewed as one clinical entity.
Mixed tumour histology is common and may affect therapy. Surgery, combined with chemotherapy, should be considered for LD.
The value of the VALSG system was implied and possible differences from small-cell lung cancer were noted.
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Small-cell carcinoma (SmCC) of the gastrointestinal tract (GIT) is
a highly aggressive and lethal neoplasm. Initially described in the
oesophagus, by Mckeown (1952) in (Mckeown, 1952), the disease
has been since reported to arise in all parts of the gastrointestinal
system (Toker, 1974; Wick et al, 1987; Matsui et al, 1991; Chetty
et al, 1993; Hoff and Pazdur, 1999; Maitra et al, 2001). Small-cell
carcinoma of the GIT is very uncommon, with a total of
approximately 544 cases having been reported in the English
literature. In light of its rarity, and the fact that it was so far studied
from an organ-centred perspective, data with regard to this entity
is extremely limited. Owing to the paucity of information and its
resemblance to the well-recognised primary SmCC of the lung
(Kelsen et al, 1980; Fer et al, 1981; Ibrahim et al, 1984), the disease
is usually managed as the latter (Nichols and Kelsen, 1989;
Huncharek and Muscat, 1995). However, the extent of the
similarity between the two entities has been recently questioned;
data from a literature review that we have performed (Brenner et al,
2004), as well as from other reports, suggest some differences
between the two (Nishimaki et al, 1997; Arai and Matsuda, 1998;
Takubo et al, 1999; Maitra et al, 2001). In order to better define the
clinical features of the disease, as well the impact of various
treatment modalities, we conducted a retrospective analysis of all
patients with gastrointestinal (GI) SmCC who were seen at
Memorial Sloan Kettering Cancer Center between 1980 and 2002.
Doing so, we intended to examine the significance of the specific
site within the GIT from which these tumours arise and whether
they can indeed be studied as one clinicopathological entity.
PATIENTS AND METHODS
The medical records of all patients with a histologically proven
diagnosis of SmCC of the GIT seen at Memorial Sloan Kettering
Cancer Center during the period 1980–2002 were reviewed. The
following data were collected for each patient: age, gender,
ethnicity, past medical and family histories, smoking and alcohol
habits, clinical presentation, anatomic location, stage, treatment
details and clinical course. The histological diagnosis of SmCC was
confirmed by the Memorial Sloan Kettering Cancer Center
pathology department in all cases. Whenever pathology slides
were available, this diagnosis was also retrospectively corroborated
by two independent pathologists (DSK, JS). Staging work-up
differed according to the primary site. However, it generally
included gastrointestinal endoscopy (colonoscopy or oesophago-
gastroscopy) and computed tomography scan of the chest,
abdomen and pelvis. Additional tests that were commonly used
were bronchoscopy, bone scan and bone marrow biopsy. In recent
years, positron emission tomography and magnetic resonance
imaging were also used occasionally.
In the absence of a specific staging system established for SmCC
of the GIT, the stage of the disease is presented according to two
staging systems, which are being used in parallel in clinical
practice. The first is the 2002 American Joint Committee on Cancer
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l(AJCC) TNM staging system for adenocarcinomas and squamous
cell carcinomas of each of the affected organs (American Joint
Committee on Cancer, 2001) The second is the system introduced
by the Veterans’ Administration Lung Study group (VALSG) for
primary SmCC of the lung (Zelen, 1973). This system consists of
two staging categories, limited and extensive disease (ED). Limited
disease (LD) is defined as a tumour contained within a localised
anatomic region, with or without regional lymph node involve-
ment. Extensive disease is defined as a tumour outside the
locoregional boundaries (Van Der Gaast et al, 1990).
Survival was analysed as disease-specific survival, calculated as
the time from diagnosis to death or to last follow-up date. This is
subject to length-biased sampling (Simon, 1980), but the time
from diagnosis to treatment was less than 30 days for 90% of
the patients, so we assumed the bias to be small. Patients dying
of causes other than SmCC of the GIT, including second
malignancies, were censored. Survival was estimated by the
Kaplan–Meier method (Kaplan and Meier, 1958). Analysis of
prognostic factors for survival included only those patients with at
least 2 months of follow-up. Comparisons of survival estimates
between subgroups according to clinical variables were performed
using the log-rank test (Mantel, 1966). Cox’s proportional-hazard
regression models were applied for multivariate analysis and to
obtain hazard ratios and 95% confidence intervals (CI) (Cox,
1972). P-values less or equal to 0.05 were considered statistically
significant.
RESULTS
Patients and tumours
In all, 64 patients with SmCC of the GIT were traced through the
Memorial Sloan Kettering Cancer Center database. This represented
less than 1% of all patients with GI malignancies seen
in the cancer centre during the period from 1980 to 2002. The
histological diagnosis was based on biopsy material in 33 patients
and on the surgical specimen in 31. In 53 cases (83%), the pathology
slides were retrospectively reviewed by one of the authors (DSK, JS)
and the diagnosis of SmCC was confirmed in all cases. None of the
patients had evidence of a primary tumour in the lung.
The clinical characteristics at presentation are outlined in
Table 1. The median age was 61 years, with almost equal gender
distribution. The median Karnofsky performance status (KPS) was
80% (range, 40–90%). The vast majority of patients (84%) were
Caucasians. The most common primary sites were the large bowel
(39%), followed by the oesophagus (30%). In all, 11 patients (20%)
had 13 metachronous second malignancies. Six of these patients
had other GI malignancies, mostly colorectal cancer. Of the 54
patients with available data, 25 (46%) had recognised predisposing
medical conditions for the development of non-SmCC tumours in
the same organ. Notably, 12 of 21 patients (57%) with colorectal
SmCC had either colonic villous adenomas (11 patients) or
ulcerative colitis (one). Eight of 18 patients (44%) with oesophageal
SmCC had at least one predisposing factor (smoking, alcohol use or
gastro-oesophageal reflux disease) and one of the two patients with
anal SmCC was homosexual and had HIV. Half of the 30 patients
with available information had a positive family history for
malignancies, primarily gastrointestinal in origin. While data with
regard to presenting symptoms were clearly specified in approxi-
mately only half of all patients, they still demonstrate a clear
pattern; the most common presentations were weight loss (52% of
patients) and pain (47%), followed by obstructive symptoms
(38%). Bleeding symptoms (20%) and a presentation with a mass
(12%) were less common. One patient presented with a full-blown
Cushing syndrome and one was diagnosed during pregnancy.
Tumour characteristics are summarised in Table 2. The most
common site for metastatic involvement at presentation was the
liver. Other common sites were the peritoneum, soft tissues, lungs
and bones. Overall, 78% of patients had a disease classified as TNM
stage III or IV and 48% had ED.
Treatment
Treatment results were analysed using the VALSG (LD vs ED)
staging system, for purposes of uniformity among the different
tumour sites and because this system was more commonly used in
the management of these patients. Treatment information was
available for 52 patients, 26 with LD and 26 with ED. The primary
treatment approach for LD varied; surgery, chemotherapy and
Table 1 Clinical features at presentation (n¼64)
Number
a Valid %
Age (years)
Median (range) 61 (37–86)
KPS
Median (range) 80 (40–90)
Gender
Male 31 48.4
Female 33 51.6
Ethnicity
Caucasian 53 84.1
Black 5 7.9
Hispanic 3 4.8
Asian 2 3.2
Anatomic location
Oesophagus
b 19 29.7
Stomach 5 7.8
Gallbladder 5 7.8
Pancreas 6 9.4
Small bowel 2 3.1
Colon 13 20.3
Rectum 12 18.8
Second malignancies
Yes 11 20.4
No 43 79.6
Predisposing medical conditions
c
Yes 25 46.3
None 29 53.7
Family history
GI malignancies 9 30.0
Other malignancies 6 20.0
None 15 50.0
Presenting symptom
Weight loss 15 51.7
Pain 18 47.4
Obstruction 15 38.5
Bleeding 8 20.0
Mass 5 12.2
KPS¼Karnofsky performance status; SmCC¼small-cell carcinoma.
aData were
missing with regard to ethnicity (one patient), other malignancies (10), predisposing
medical condition (10), family history (34), weight loss (35), pain (26), obstruction
(25), bleeding (24) and mass (23).
bIncluding four patients with tumours in gastro-
oesophageal junction.
cPatients with at least one predisposing medical conditions for
the development of non-SmCC tumours in the same organ: smoking (oesophageal,
gastric and pancreatic tumours), alcohol use (oesophagus), gastro-oesophageal reflux
disease (oesophagus), biliary disease (gallbladder), pancreatitis (pancreas), polyps
(large bowel) and homosexuality (anus).
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lradiotherapy were all used, either alone or as part of a variety of
combined modality treatment schemes. On the other hand, in 20 of
the 26 patients (77%) with ED, primary treatment consisted
exclusively of chemotherapy. The other patients were treated by
palliative surgery (three patients), radiotherapy (one) or by
supportive care (two).
Of the 17 patients with LD who received primary treatment with
surgery, alone or with other treatment modalities, three patients,
two of whom were treated by surgery alone, are still alive with no
evidence of disease (ANED) 15, 94 and 99 months from diagnosis.
One patient died with no evidence of disease almost 9 years from
diagnosis. Three of the operated patients died from postoperative
complications; in seven of the remaining 14 patients (50%),
locoregional control was preserved. Eight patients received radio-
therapy as part of their primary treatment. At the time of the
analysis, only one of these remained free of disease recurrence.
Locoregional failure was common; six of seven patients for whom
such data were available had locoregional progression after
radiation. In total, 16 patients with LD received chemotherapy,
12 of whom received it in conjunction with either surgery or
radiotherapy. Of these, two remained ANED for at least 64 and 94
months and one expired with no evidence of recurrence after
almost 9 years. Locoregional control was preserved in five (31%) of
these patients.
Overall, for both LD and ED, 36 patients received chemotherapy,
with or without other modalities, as their primary treatment. Half
the patients were treated by a combination of etoposide and
platinum compound. The rest of the patients were treated by a
variety of regimens, such as 5-fluorouracil/leucovorin and CAV
(cyclophosphamide, doxorubicin and either vincristine or etopo-
side). A total of of 14 patients were nonevaluable for response; they
either received chemotherapy with concurrent radiotherapy or in
the adjuvant setting. Of the 22 evaluable patients, two complete
(9%) and six partial responses (27%) were observed, with an
overall objective response rate of 36%. The median duration of
response was 8 months (range, 4–16 months). With small absolute
numbers, regimens that seemed to have been associated with
significant clinical activity, in the order of 50% objective response
rate, are the platinum-based and the CAV regimens. Data on newer
agents, such as paclitaxel and irinotecan, were very limited.
Clinical course
At a median follow-up of 13 months (range, 1–107 months), six of
the 64 patients (9%) were ANED, 16 patients (25%) were alive with
disease, one patient (2%) died without any evidence of disease and
41 patients (64%) died of disease. The 1- and 2-year survival rates
for the entire group were 49 and 23%, respectively. Four patients
(6%) survived more than 5 years. The median survival was 11
months (range, 1–107 months) (Figure 1).
Of the 48 patients with known progression status and at least 1
month of follow-up, progression was documented in 43 patients
(90%). First progression was locoregional in 11 patients (26%),
distant in 12 (28%), mixed in 10 (23%) and unspecified in 10
(23%). Data of the specific location of metastases, available for
80% of the patients, demonstrated a distinct pattern. The most
common sites of metastases, at any time during the follow-up, were
lymph nodes (75%) and liver (53%), followed by the peritoneum
(28%), soft tissues (25%) and lungs (22%). Bone (17%), brain and
adrenals (10% each) were less commonly involved.
Table 2 Tumour characteristics (n¼64)
Number
a Valid %
Other histological component
Adenocarcinoma 13 21.0
Squamous cell carcinoma 9 14.5
Anaplastic carcinoma 1 1.6
Pure SmCC 39 62.9
T stage
I 5 9.8
II 9 17.7
III 25 49.0
IV 12 23.5
N status
N+ 34 66.7
N0 17 33.3
M status
M1 35 55.6
M0 28 44.4
Sites of metastases at presentation
b
Liver 22 37.3
Lung 6 10.5
Adrenal 1 1.8
Peritoneum 9 15.2
Soft tissue 7 12.3
Bone 6 10.3
Brain 1 1.8
Number of metastatic sites
0 28 44.4
1 11 17.5
2 13 20.6
X3 11 17.5
TNM stage
c
I 4 6.8
II 9 15.2
III 11 18.6
IV 35 59.3
Extent
Limited 33 52.4
Extensive 30 47.6
SmCC¼small-cell carcinoma.
aData were missing with regard to other histological
component (2 patients), T stage (13), N status (13), M status (1), number of
metastatic sites (1), TNM stage (5) and extent of disease (1).
bInvolvement of the
following sites was not specified: liver (5 patients), lung (7), adrenal (8), peritoneum
(5), soft tissue (7), bone (6) and brain (8).
cAccording to the 2002 AJCC staging
system.
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Figure 1 Disease-specific survival by the extent of disease (n¼59).
Within parenthesis is the number of patients in each subgroup.
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lPrognostic factors
The results of a univariate analysis of various patient and tumour
variables are depicted in Table 3. Several factors were found to
correlate with patient outcome: performance status, weight loss, T
stage, N and M status, TNM stage and extent of disease (LD vs ED).
The extent of disease had a strong impact on survival; patients with
LD had 72% 1-year survival as compared with those with ED, who
had 29% 1-year survival (Po0.01) (Figure 1). Patients with TNM
stages I, II and III had similar survival profiles and their prognosis
was better than stage IV patients (P¼0.04). When TNM stages I, II
and III were combined, the resulting grouping (stage I–III vs IV)
had am impact on survival, which was similar to that of the extent
of disease (81 vs 31% 1-year survival, Po0.01).
Of the various multivariate models of survival applied, the one
selected was chosen because of its clinical relevance, completeness
of the data with regard to the included variables and a good
statistical fit. According to this model, which included age, gender,
anatomic location and extent of disease, only the last one retained
statistical significance, with a hazard ratio of 4.0 (95% CI 2.0–8.2,
Po0.01). When the extent of disease according to VALSG staging
system was replaced, in the same model, by TNM stage, this also
Table 3 Survival by patient and tumour characteristics
Univariate analysis
Overall survival 1-year survival Median survival, months (95% CI) P-value
Age (years)
p60 (n¼29) 45% 63% 20.3 (10.8–22.3) 0.18
460 (n¼31) 32% 43% 10.4 (5.6–21.9)
Gender
Male (n¼29) 41% 34% 10.4 (7.6–19.8) 0.52
Female (n¼31) 35% 68% 203 (14.9–23.1)
KPS
p80 (n¼22) 18% 27% 7.0 (4.4–11.4) o0.01
480 (n¼18) 53% 82% 20.3 (15.8–NR)
Anatomic location
a
Upper GIT (n¼24) 25% 43% 9.2 (6.1–22.3) 0.37
Lower GIT (n¼24) 54% 67% 19.6 (11.4–NR)
Other (n¼12) 33% 48% 10.8 (4.4–NR)
Weight loss
Yes (n¼14) 36% 36% 7.6 (3.9–15.8) o0.01
None (n¼14) 43% 84% 21.9 (14.9–NR)
Obstruction
Yes (n¼14) 36% 55% 15.8 (8.5–28.0) 0.51
None (n¼23) 39% 63% 19.8 (10.8–26.3)
Other histological component
Yes (n¼21) 62% 50% 11.4 (7.6–21.0) 0.14
None (n¼37) 27% 61% 21.1 (4.4–NR)
T stage
I( n¼5) 40% 80% 21.9 (2.0–NR) o0.01
II (n¼8) 25% 63% 21.3 (7.6–NR)
III (n¼22) 64% 71% 26.3 (11.0–NR)
IV (n¼12) 8% 27% 4.4 (3.8–14.9)
N status
N+ (n¼29) 28% 33% 7.6 (4.4–14.9) 0.02
N0 (n¼17) 41% 88% 22.0 (19.8–28.0)
M status
M1 (n¼32) 28% 31% 8.3 (4.4–11.0) o0.01
M0 (n¼27) 52% 79% 22.0 (19.8–28.0)
TNM stage
I( n¼4) 25% 75% 19.8 (2.0–22.0) 0.04
II (n¼9) 44% 89% 26.3 (20.3–NR)
III (n¼10) 60% 75% 28.0 (10.4–NR)
IV (n¼32) 28% 31% 8.3 (4.4–11.0)
Extent
Limited (n¼32) 50% 72% 21.9 (15.8–NR) o0.01
Extensive (n¼27) 26% 29% 5.8 (4.4–10.8)
NR¼not reached.
aUpper GIT¼oesophagus and stomach; lower GIT¼large bowel and anus; other¼gallbladder, pancreas and small bowel; KPS¼Karnofsky performance
status; SmCC¼small-cell carcinoma.
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lretained significance, although its P-value was higher (P¼0.03). It
is of note that in neither of these models performance status and
weight loss were included, due to the high percentage of missing
data. However, models that included them, with smaller numbers
of available patients, did suggest independent prognostic impact
for these two factors (data not shown).
Influence of specific site
In order to examine the importance of the specific site from which
SmCC of the GIT arise, tumours were divided into three groups
according to their anatomic location: upper GIT (oesophagus and
stomach), lower GIT (large bowel and anus) and other (gall-
bladder, pancreas and small bowel). As seen in Table 4, most of the
clinicopathological features of these groups were very similar,
including the proportion of mixed histology and ED, response rate
to chemotherapy and incidence of progression. In addition, on
univariate analysis, no influence of anatomic location on survival
was identified. The only notable difference between the groups was
in their profile of predisposing medical conditions, as described
above.
DISCUSSION
Small-cell carcinoma of the GIT is a very rare malignancy.
Knowledge of this disease is derived predominantly from small
series that are all organ specific (e.g. SmCC of the oesophagus) and
from extrapolations from what is perceived as an almost identical
entity, primary SmCC of the lung. We recently reviewed the
literature with regard to SmCC of the GIT. We noted a paucity of
information on the disease, and wondered if the commonly held
view with regard to its similarity with SmCC of the lung was valid
(Brenner et al, 2004). In order to expand the available databases,
we conducted the current study, trying to exploit a combination of
a large database and a somewhat different approach; to the best of
our knowledge, this is the first study of this disease focusing on
these tumours throughout the GIT and not on the individual
location within the GIT from which they arise.
The present study largely confirmed previous concepts of the
epidemiology and clinical presentation of the disease. These
include its rarity (Remick et al, 1987; Acea Nebril et al, 1996), the
predominance of older patients (Medgyesy et al, 2000; Maitra et al,
2001), the characteristic presentation (Wick et al, 1987; Hoff and
Pazdur, 1999), including occasional symptoms that are secondary
to hormone production (Taniguchi et al, 1973; Chejfec and Gould,
1977; Doherty et al, 1984) and the typical advanced stage at
diagnosis (Matsui et al, 1991; Bennouna et al, 2000). The high
proportion of oesophageal tumours is also in agreement with
previous reports (Ibrahim et al, 1984; Remick et al, 1987); 30% of
our patients and half of the cases reported in the literature had
oesophageal tumours. In concordance with the literature, the colon
and rectum was the leading location in our study, involved in 39%
of the patients (Hoff and Pazdur, 1999). While we observed a
nearly equal gender distribution, there seems to be a trend in the
literature toward a male predominance in this disease (Medgyesy
et al, 2000; Madroszyk et al, 2001). Other epidemiological features
of our patient population, the high prevalence of metachronous
cancers and family history of cancer, were not reported previously.
At present, the pathogenesis of SmCC of the GIT is obscure. A
leading hypothesis is that these tumours derive from a pluripotent
stem cell, which can also give rise to adeno and squamous cell
carcinomas. (Ho et al, 1984) Two findings in our study, confirming
previous reports, seem to be in support of this theory. First, the
high proportion of tumours with elements of adeno or squamous
cell carcinoma (Craig et al, 1995; Maitra et al, 2001). Second, the
high frequency of medical conditions, which are associated with
increased risk for non-SmCC tumours in the same organ (Burke
et al, 1991; Chetty et al, 1993; Yaziji and Broghamer, 1996; Lam
et al, 2000). The high prevalence of mixed tumour histology may
influence treatment. Current chemotherapeutic agents almost
invariably fail to eliminate tumour cells of adeno or squamous
phenotype completely. Hence, it is possible that in the presence of
complete clinical response to chemotherapy, the recurrent tumour
will frequently consist of the non-SmCC clones. For patients with
LD, this implies a potential role for local therapies.
Small-cell carcinoma of the GIT has been associated with a
dismal prognosis. The median survival was described in the range
of 6–12 months or of several weeks, for treated or untreated
patients, respectively (Redman and Pazdur, 1987; Wick et al, 1987;
O’Byrne et al, 1997). In our study, all but two patients were treated;
the median survival was 11 months and 2-year survival was 23%.
Similar to others, we also observed a small group (6%) of long-
term survivors. The pattern of spread we noted partially concurs
with prior reports: while hepatic and nodal involvements were also
very frequent in our study, peritoneal and soft-tissue metastases
seemed to have been more common than described previously
(Matsui et al, 1991; Nishimaki et al, 1997; Hoff and Pazdur, 1999).
Extensive disease is almost invariably treated by systemic
chemotherapy (Nichols and Kelsen, 1989; Huncharek and Muscat,
1995). In contrast, the treatment approach for LD, a potentially
Table 4 Comparison between SmCC arising at different GI sites
a
(n¼64)
Upper GIT
(n¼24)
Lower GIT
(n¼27)
Other
(n¼13)
Median age (years) 65 55 59
Male gender 17/24 (71) 9/27 (33) 5/13 (38)
Second malignancies 6/22 (27) 1/22 (5) 4/10 (40)
Mixed histology 9/23 (39) 10/27 (37) 4/12 (33)
Extensive disease 10/23 (43) 13/27 (48) 7/13 (54)
Response to chemotherapy 3/8 (37) 3/9 (33) 2/5 (40)
Progression rate 18/21 (86) 20/21 (95) 10/13 (77)
GIT: gastrointestinal tract; SmCC¼small-cell carcinoma.
aTumours were grouped
into three categories: upper GIT (oesophagus, GEJ and stomach), lower GIT (large
bowel and anus) and other (hepatobiliary system and small bowel).
Table 5 Comparison of features from the current study with those of
SmCC of the lung
Similarities Dissimilarities
Neuroendocrine features, with
occasional symptomatic
hormone production
Smaller proportion of smokers (45 vs 90%
in SmCLC
a)
High metastatic potential Presence of predisposing medical
conditions for non-SmCC tumours in the
same organ
Pattern of spread Higher rate of non-SmCC components (37
vs 1–3% in most SmCLC series)
Typical overall chemosensitivity Suggested higher proportion of LD at
presentation (52 vs 30–40% in SmCLC)
Overall dismal prognosis Larger proportion of long-term survivors
following surgery (4 of 17 vs 1% in SmCLC)
Prognostic impact of extent of
disease and performance status
Suggested lower efficacy of radiotherapy in
preserving LRC (14% vs 70% in SmCLC)
Lower response rate to CAV and platinum-
based chemotherapy (50 vs 80–90% (LD)
and 60–80% (ED) in SmCLC)
LRC¼locoregional control; CAV¼cyclophosphamide, doxorubicin and either
vincristine or etoposide; LD¼limited disease; ED¼extensive disease;
SmCC¼small-cell carcinoma.
aAccepted figures in the literature for SmCC of the
lung (SmCLC).
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lcurable condition, is presently neither consistent nor uniform;
while some authors used only local therapies, mostly surgery and
occasionally radiotherapy, others advocated the use of chemother-
apy, even alone, in these patients (Kelsen et al, 1980; Arai and
Matsuda, 1998). Primary treatment of LD in our study varied. With
small absolute numbers, this study suggests a potential role for
surgery for LD; half of the operated patients retained locoregional
control, and four of the six long-term survivors had surgery; two of
them with no other treatment. Our study also supports the
effectiveness of chemotherapy on survival in this disease; three of
the long-term survivors received chemotherapy too. Six patients
were treated by a combination of surgery and chemotherapy. Two
of these had no evidence of disease for over 7 years and
locoregional control was preserved in three. At present, in the
absence of data derived from prospective clinical trials, it seems
reasonable to treat patients with LD with pre- or postoperative
chemotherapy.
The chemotherapy regimens used in our institution were mostly
ones used at that time to treat pulmonary SmCC. A 50% response
rate was noted for platinum-based and CAV regimens, lower than
the 70–90% rate described before (Redman and Pazdur, 1987;
Huncharek and Muscat, 1995; Bennouna et al, 2000). Whether this
discrepancy reflects the fact that most previously reported
treatment results derived from studies on oesophageal SmCC or
the larger number of patients in our study, the current rate may
represent more realistically the impact of chemotherapy in this
disease. Compared with pulmonary SmCC, the apparently lower
response rate to chemotherapy in GI SmCC may reflect the
suggested higher rate of mixed tumour histology in the latter. In
any case, from our study and others, cisplatin-based combinations
can be presently viewed as the chemotherapeutic regimens of
choice in GI SmCC (Nichols and Kelsen, 1989; Hoff and Pazdur,
1999). One should consider the frequent mixed tumour histology
in this disease. Of the various options, a combination of cisplatin
and irinotecan can potentially provide significant activity against
both components. This regimen was shown to be superior to
cisplatin/etoposide in pulmonary SmCC (Noda et al, 2002) and to
be very active in gastro-oesophageal adenocarcinoma (Enzinger
et al, 1998). Moreover, irinotecan is now considered one of the two
most effective agents against colorectal cancer (Rougier and Mitry,
2001). Recently, a response of cisplatin-resistant gastrointestinal
SmCC to irinotecan was reported (Sairenji et al, 2001).
The current study has identified two prognostic factors in GI
SmCC, the extent of disease according to the VALSG classification
and TNM stage, and the prognostic impact of two others,
performance status and weight loss, was implied. While pre-
liminary, our study seems to suggest that clear prognostic
stratification exists only between TNM stages I–III and stage IV.
If confirmed, this may lead to the acceptance of the simpler VALSG
system as the primary staging method for GI SmCC, similar to
pulmonary SmCC. In the only prognostic factor analysis in that
disease published to date, Casas et al (1997) also demonstrated the
prognostic impact of the extent of disease. In their study, involving
199 previously reported patients with oesophageal SmCC, the
median survival of patients with LD and ED was 8 and 3 months,
respectively (Po0.01) (Casas et al, 1997). The prognostic influence
of both the extent of disease and performance status has also been
demonstrated in primary SmCC of the lung (Radford et al, 1992;
Lassen et al, 1999; Paesmans et al, 2000; Nicholson et al, 2002).
Our study may offer an opportunity to test the widely accepted
hypothesis that SmCC of the GIT and the lung are nearly identical.
Outlined in Table 5 are representative differences and similarities
between findings from our study and known features of primary
lung SmCC. Despite an extensive overlap, the comparison seems to
imply some differences between the two entities. Of importance,
these include a differential efficacy of various treatment modalities,
such as a role for surgery in GI SmCC. Both the disparities and
similarities identified here were suggested before (Nichols and
Kelsen, 1989; Matsui et al, 1991; Nishimaki et al, 1997). Moreover,
initial reports seem to imply only partial overlap between the
molecular biology patterns of the two entities (Takubo et al, 1999;
Lam et al, 2000; Maitra et al, 2001). This suggests the need for
further investigation, and the drawback of managing SmCC of the
GIT totally on the basis of extrapolations from lung SmCC.
In summary, the present study suggests that SmCC arising from
various locations within the GIT can be viewed and treated as a
one clinical entity. We noted the prevalence of mixed tumour
histology, the value of the VALSG staging system and the potential
role of surgery, combined with chemotherapy, in the treatment of
LD. Nonetheless, more data are required before any solid clinical
guidelines are established. Since prospective clinical trials are
unlikely in this rare disease, large retrospective surveys, such as
ours, and correlative studies, represent the main source of this
information.
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